Biosimilars Snapshot
Innovative brands need to revisit their biosimilar plans to ensure they can maximize their time over the competition
Blog Post
Cell & Gene Therapy
Most of the therapeutic candidates target rare diseases and cancers which are difficult to treat and do not have a curative therapy
Commercial Trends to Act on in China’s Pharmaceutical Industry
The slowdown of recent growth in the Chinese Pharma market demonstrates potential for western companies to partner with their Chinese counterparts for mutual benefit.
Complex Diseases and Digital Health Can Push Each Other to Innovate
Digital health can speed the identification and approval of agents in oncology, rare diseases, immunology and neurology.
Antibody Drug Conjugates: Shaping the Future Treatment Paradigms in Solid Tumors
As ADCs continue to get incorporated in the treatment landscape across several solid tumors, data emerging from the next wave of ADCs add to the excitement.
Too Big to Ignore: What CI Needs to Do to Make the China Market Manageable
Chinese pharmaceutical companies present both an opportunity and a threat to their international counterparts. In this blog, we explore what Western pharmaceutical businesses need to do as the world’s manufacturing hub begins building a reputation for quality.
The Key to Successfully Navigating Chinese Pharmaceutical Regulations
The Chinese regulatory landscape is very different compared to that of the rest of the world. Can businesses bridge the gap between the East and West?
ASH 2020 Highlights – Acute Myeloid Leukemia (AML)
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they might affect the treatment paradigm in AML.
ASH 2020 – Multiple Myeloma (MM)
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they might affect the treatment paradigm in MM.
ASH 2020 Highlights – Chronic Lymphocytic Leukemia (CLL)
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they might affect the treatment paradigm in CLL.
LinkedIn
Twitter
Facebook